JAMA|2025|Kushner R, Almandoz J, Rubino D|10 citations
PMID: 40728833
A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
OBJECTIVE: Studies have demonstrated dose-dependent efficacy of glucagon-like peptide 1 receptor agonists for glycemic control and body weight. The aim of this trial was to characterize the dose-dependent effects of semaglutide (up to 16 mg/week) in…
The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5-6, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recen…
Obesity in heart failure (HF) patients often experience a significant burden of symptoms and physical limitations. Semaglutide, a glucagon-like peptide 1 receptor agonist, has a beneficial impact on cardiovascular outcomes in obese patients, but its…
INTRODUCTION: Semaglutide injection 2.4 mg (Wegovy; hereafter referred to as semaglutide) was approved by the US Food and Drug Administration in June 2021 for chronic weight management in adults with overweight or obesity. This study aimed to evaluat…
: Heart failure (HF) among patients with type 2 diabetes (T2DM) is linked to significant morbidity and mortality, despite the increased availability of new drug therapy. This study aims to investigate subclinical changes in patients with HF stage A (…
AIMS: Nearly 42% of adults in the United States have obesity, a significant risk factor for many cardiometabolic diseases and cancers. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are promising interventions for weight loss, but their efficac…
Semaglutide (Ozempic®), administered as a weekly subcutaneous injection up to 1.0 mg, holds a privileged place in the international guidelines for the management of type 2 diabetes. Commercialized under the trade name Wegovy®, semaglutide is also ind…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are crucial in managing type 2 diabetes mellitus (T2DM) and obesity. Agents like dulaglutide, semaglutide, and liraglutide mimic endogenous GLP-1, enhancing insulin secretion and promo…
BACKGROUND/OBJECTIVES: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important common comorbidity in subjects with type 2 diabetes, and liver fibrosis is a factor directly related to its prognosis. Glucagon-like peptide-1 rec…
BACKGROUND: Emotional reactions to treatment could affect treatment adherence and treatment outcomes, and it is therefore important to assess the emotional impact of treatment and consider this impact in clinical decision-making. The Emotional Impact…
The rising prevalence of youth-onset type 2 diabetes (T2D) in children necessitates early intervention with tight glycemic control, obesity medications, and metabolic and bariatric surgery (MBS). Insulin and metformin are standard treatments, but add…
Semaglutide, a novel drug, has shown potential benefits for heart failure with preserved ejection fraction (HFpEF) and obesity in early trials. This study aims to evaluate the efficacy and safety of semaglutide and other glucagon-like peptide-1 (GLP-…
AIMS: Individuals with type 1 diabetes are at high risk of cardiovascular disease (CVD) and chronic kidney disease (CKD) even with optimal glycaemic control. The Steno 1 study will test a strategy of intensified care based on multifactorial intervent…